Immunophenotypic features of AML blasts cultured with FLT3-L, TPO, and SCF
. | CD14+ cells (MFIs) . | . | CD15+ cells (MFIs) . | . | ||
|---|---|---|---|---|---|---|
| Culture with cytokines . | − . | + . | − . | + . | ||
| Patient no. 13; AML4 | 39% ± 5% (44 ± 7) | < 5% | 35% ± 8% (22 ± 8) | 22% ± 5% (39 ± 7) | ||
| Patient no. 23; AML5 | 23% ± 5%* (47 ± 5) | 58% ± 7%* (64 ± 15) | 34% ± 3% (52 ± 8) | 16% ± 5% (45 ± 5) | ||
| Patient no. 55; AML 1 | < 5% | < 5% | 8% ± 3%* (14 ± 5) | 41% ± 8%* (34 ± 4) | ||
| Patient no. 59; AML4 | 15% ± 5% (101 ± 25) | < 5% | 19% ± 4% (77 ± 9) | 25 ± 4% (90 ± 12) | ||
. | CD14+ cells (MFIs) . | . | CD15+ cells (MFIs) . | . | ||
|---|---|---|---|---|---|---|
| Culture with cytokines . | − . | + . | − . | + . | ||
| Patient no. 13; AML4 | 39% ± 5% (44 ± 7) | < 5% | 35% ± 8% (22 ± 8) | 22% ± 5% (39 ± 7) | ||
| Patient no. 23; AML5 | 23% ± 5%* (47 ± 5) | 58% ± 7%* (64 ± 15) | 34% ± 3% (52 ± 8) | 16% ± 5% (45 ± 5) | ||
| Patient no. 55; AML 1 | < 5% | < 5% | 8% ± 3%* (14 ± 5) | 41% ± 8%* (34 ± 4) | ||
| Patient no. 59; AML4 | 15% ± 5% (101 ± 25) | < 5% | 19% ± 4% (77 ± 9) | 25 ± 4% (90 ± 12) | ||
Enriched populations of AML blasts (4 × 104 to 5 × 104/mL) were seeded in triplicate at day 0 in culture medium supplemented with thrombopoietin, FLT3-ligand, and stem cell factor as described in “Materials and methods.” At day 0 and day 7, they were labeled by using FITC-conjugated mAb to CD14 or CD15. The mAb binding was measured by flow cytometry relative to isotype-matched control antibodies as described. 19 Data are means ± 1 SD calculated from quadruplicate samples. The % indicates the percentages of CD14+ and CD15- positive cells; mean fluorescence intensities (MFIs) are indicated in parentheses. This is 1 experiment representative of 2.
Data of cytokine-treated blasts are significantly different from those of uncultured blasts (P < .05, Mann-Whitney test).